Page last updated: 2024-11-07

spironolactone and Depressive Disorder, Treatment-Resistant

spironolactone has been researched along with Depressive Disorder, Treatment-Resistant in 1 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Juruena, MF1
Pariante, CM1
Papadopoulos, AS1
Poon, L1
Lightman, S1
Cleare, AJ1

Trials

1 trial available for spironolactone and Depressive Disorder, Treatment-Resistant

ArticleYear
The role of mineralocorticoid receptor function in treatment-resistant depression.
    Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:12

    Topics: Canrenone; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Female; Humans; Hydrocort

2013